Gianluigi Savarese is an Italian cardiologist, currently Associate Professor of Cardiology at the Department of Medicine, Karolinska Institutet, Stockholm, Sweden and Consultant in Heart Failure at the Karolinska University Hospital, Stockholm, Sweden. He received his MD from Federico II University in Naples (Italy) in 2010 and underwent cardiology residency (2011-2016) at the same Institution. In 2013-2014 he was guest fellow at the Center for Molecular Cardiology of the University of Zurich (Switzerland) headed by Prof TF Luscher, where he investigated the molecular mechanisms of heart failure. In 2017 he got the title of heart failure specialist from the University of Zurich, the Heart Failure Association of the European Society of Cardiology and the European Heart Academy. In 2018 he received his PhD from the Karolinska Institutet (Stockholm-Sweden), with a thesis entitled “Biomarkers for eligibility and surrogate endpoints in heart failure trials”. He is currently fellow of the European Society of Cardiology (FESC) and of the Heart Failure Association (FHFA), former secretary and current board member of the ESC working group on cardiovascular pharmacotherapy and board member of the Heart Failure Association of the European Society of Cardiology.
Over the last 5 years, he has published more than 100 articles on top peer reviewed journals and presented over 50 abstracts at international congresses (ESC, HFA, AHA, ACC). Major focus in his research is heart failure, with a particular interest in phenotyping heart failure with preserved and mid-range ejection fraction, biomarkers and selection criteria for HF clinical trials. He is heavily involved in registry studies (Swedish Heart Failure Registr, HFA registry) and he has several research collaborations in Europe and USA. He has worked as reviewer for several peer-reviewed journals (EHJ, EJHF, JACC, Annals of Internal Medicine, International Journal of Cardiology, Journal of Cardiovascular Medicine, Journal of Cardiac Failure, European Heart Journal - Cardiovascular Pharmacotherapy, etc) and he is currently editor for Plos One, European Heart Journal Open and and European Heart Journal – Case reports.